Concepedia

Publication | Closed Access

Phase I Trial of Docetaxel With Estramustine in Androgen-Independent Prostate Cancer

DOI

312

Citations

28

References

1999

Year

Daniel P. Petrylak, Robert B. MacArthur, John F. O’Connor, Gary Shelton, Timothy Judge, Joshua Balog, Charles Pfaff, Emilia Bagiella, Daniel F. Heitjan, Robert Fine,
Journal of Clinical Oncology

Abstract

The recommended phase II dose of docetaxel combined with estramustine is 70 mg/m2 in MPT patients and 60 mg/m2 in EPT patients. This combination is active in men with androgen-independent prostate cancer.

References

YearCitations

Page 1